Stephens Inc. AR Boosts Stock Holdings in Boston Scientific Corporation $BSX

Stephens Inc. AR increased its stake in Boston Scientific Corporation (NYSE:BSX) by 92.5% during the 3rd quarter, Holdings Channel reports. The fund owned 20,880 shares of the medical equipment provider’s stock after purchasing an additional 10,034 shares during the quarter. Stephens Inc. AR’s holdings in Boston Scientific were worth $2,039,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Steph & Co. acquired a new stake in Boston Scientific in the 3rd quarter valued at about $25,000. Financial Consulate Inc. purchased a new stake in shares of Boston Scientific during the third quarter worth approximately $25,000. FWL Investment Management LLC purchased a new position in Boston Scientific in the second quarter worth approximately $26,000. Sound Income Strategies LLC grew its holdings in Boston Scientific by 90.9% during the 2nd quarter. Sound Income Strategies LLC now owns 252 shares of the medical equipment provider’s stock worth $27,000 after acquiring an additional 120 shares in the last quarter. Finally, Kilter Group LLC purchased a new stake in shares of Boston Scientific in the 2nd quarter valued at approximately $30,000. 89.07% of the stock is owned by institutional investors and hedge funds.

Boston Scientific Price Performance

Shares of NYSE:BSX opened at $88.13 on Friday. Boston Scientific Corporation has a one year low of $85.98 and a one year high of $109.50. The stock has a market capitalization of $130.65 billion, a price-to-earnings ratio of 47.13, a PEG ratio of 1.56 and a beta of 0.67. The company has a 50-day simple moving average of $96.90 and a 200-day simple moving average of $100.29. The company has a debt-to-equity ratio of 0.47, a quick ratio of 0.96 and a current ratio of 1.51.

Boston Scientific (NYSE:BSX) last released its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.71 by $0.04. The firm had revenue of $5.07 billion for the quarter, compared to analyst estimates of $4.97 billion. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The business’s revenue was up 20.3% on a year-over-year basis. During the same quarter last year, the company posted $0.63 earnings per share. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS. On average, analysts predict that Boston Scientific Corporation will post 2.85 EPS for the current year.

Analyst Upgrades and Downgrades

BSX has been the subject of several recent analyst reports. Citigroup reaffirmed a “buy” rating on shares of Boston Scientific in a research report on Wednesday. The Goldman Sachs Group reaffirmed a “buy” rating and set a $112.00 price objective on shares of Boston Scientific in a research report on Friday, January 9th. Oppenheimer cut their target price on Boston Scientific from $125.00 to $100.00 and set an “outperform” rating on the stock in a research report on Friday. Canaccord Genuity Group decreased their target price on Boston Scientific from $132.00 to $131.00 and set a “buy” rating for the company in a research note on Wednesday, December 17th. Finally, Barclays lifted their price target on shares of Boston Scientific from $133.00 to $136.00 and gave the stock an “overweight” rating in a research note on Thursday, October 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating and two have given a Hold rating to the stock. Based on data from MarketBeat, Boston Scientific presently has a consensus rating of “Buy” and an average price target of $123.89.

Insider Activity

In other news, EVP Arthur C. Butcher sold 17,313 shares of the company’s stock in a transaction that occurred on Monday, December 1st. The stock was sold at an average price of $101.55, for a total transaction of $1,758,135.15. Following the completion of the sale, the executive vice president owned 23,600 shares in the company, valued at $2,396,580. This represents a 42.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, Director Ellen M. Zane sold 12,891 shares of Boston Scientific stock in a transaction on Thursday, November 6th. The shares were sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the completion of the transaction, the director owned 24,134 shares in the company, valued at approximately $2,371,889.52. This trade represents a 34.82% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 93,095 shares of company stock valued at $9,305,450. Company insiders own 0.50% of the company’s stock.

Boston Scientific News Summary

Here are the key news stories impacting Boston Scientific this week:

• Positive Sentiment: Acquisition expands addressable market — The agreement to buy Penumbra (~$14.5B enterprise value) gives Boston Scientific scaled entry into mechanical thrombectomy and neurovascular devices, which management says accelerates growth in fast-growing vascular segments. Read More.
• Positive Sentiment: Wall Street support remains — TD Cowen reiterated a Buy and other analysts emphasize the deal as a strategic growth catalyst and valuation support ahead of 2026 expectations. Read More.
• Neutral Sentiment: Price-target and analyst notes are mixed — Oppenheimer trimmed its target from $125 to $100 but kept an Outperform rating, indicating continued upside though with more cautious near-term expectations. Read More.
• Neutral Sentiment: Technical/turnaround commentary — Some market commentators note BSX is technically oversold and that consensus earnings revisions are turning positive, which could support a rebound over time. Read More.
• Neutral Sentiment: Smaller tuck-ins continue — Boston Scientific’s other recent deals (e.g., Valencia Technologies) broaden product offerings in urology and ITNS, a modest near-term boost versus the Penumbra scale. Read More.
• Negative Sentiment: Shares sold off on the deal announcement — The market reacted negatively to the size/structure of the transaction and near-term uncertainty, and BSX shares traded down after the news. Read More.
• Negative Sentiment: Legal/approval uncertainty — Law firms have launched investor inquiries into the adequacy of Penumbra’s sale process and price; this increases deal execution risk and could prolong integration or regulatory review. Read More.
• Negative Sentiment: Derivative-market hedging and bearish interest spiked — Unusually large put option volume indicates some investors are hedging or betting on further downside, adding volatility risk. Read More.
• Negative Sentiment: Mixed analyst commentary and skeptic pieces — Several independent commentaries and Seeking Alpha pieces highlight concerns about price paid and strategic fit, underscoring near-term skepticism despite long-term promise. Read More.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.